MaaT Pharma Releases its 2024 Financial Calendar

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, releases its 2024 financial calendar*:

March 28, 2024: Publication of 2023 annual financial results
May 14, 2024: Publication of revenues for Q1 2024
May 28, 2024: Annual General Shareholders Meeting
September 19, 2024: Publication of half year financial results H1
November 5, 2024: Publication of revenues for Q3 2024

*Indicative calendar could be subject to change.

All information about the Company and its presentations to investors are available in the Investors section of its website: www.maatpharma.com/investors

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240307463341/en/

MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 invest@maat-pharma.com

MaaT Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 media@maat-pharma.com

Trophic Communications – Corporate Communications Jacob VERGHESE or Priscilla PERRIN +49 151 7441 6179 maat@trophic.eu

Maat Pharma (EU:MAAT)
過去株価チャート
から 3 2024 まで 4 2024